Skip to content

Effect of Ursodeoxycolic acid on neonatal jundice

Effect of Ursodeoxycolic acid on serum bilirubin levels in term neonateswith indirect hyperbilirubinemia

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20220723055524N1
Enrollment
80
Registered
2023-10-14
Start date
2023-10-23
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperbilirubinemia. Neonatal jaundice, unspecified

Interventions

Intervention 1: Intervention group: full-term infants over 5.2 kg and more than 72 hours after birth, who do not have evidence of direct jaundice and sepsis, treated with UDCA capsules at a dose of 15

Sponsors

Babol University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Days to 30 Days

Inclusion criteria

Inclusion criteria: The criteria for inclusion in the study include full-term infants (37-41 weeks) postnatal age greater than or equal to 72 hours and weighing more than 2.5 kg billirubin T<18

Exclusion criteria

Exclusion criteria: direct hyperbillirubinemia symptoms of sepsis prematurity

Design outcomes

Primary

MeasureTime frame
Accelerate the reduction of bilirubin. Timepoint: Measurement of total bilirubin level at 12, 24, 36 and 48 hours. Method of measurement: Total bilirubin serum level by diazo method.

Secondary

MeasureTime frame
Duration of hospitalization. Timepoint: During the study by measuring serum bilirubin. Method of measurement: measuring serum bilirubin.;Time of separation between mother and baby. Timepoint: During the study by measuring serum bilirubin. Method of measurement: measuring serum bilirubin.;Reducing treatment costs. Timepoint: During the study by measuring serum bilirubin. Method of measurement: measuring serum bilirubin.;Reducing parents' worries are secondary outcomes. Timepoint: During the study by measuring serum bilirubin. Method of measurement: measuring serum bilirubin.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Musa Ahmadpoor

Babol University of Medical Sciences

r.ehsani@mubabol.ac.ir+98 11 3235 4951

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026